3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4 Argatroban Intermediate Factory 98.0%

Short Description:

Chemical Name: 3-Methyl-8-Quinolinesulphonyl Chloride

CAS: 74863-82-4

Appearance: White Crystalline Powder

Purity: >98.0% (HPLC)

Intermediate of Argatroban (CAS 74863-84-6), a Synthetic Thrombin Inhibitor. Antithrombotic

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 3-Methyl-8-Quinolinesulphonyl Chloride
Synonyms 3-Methylquinoline-8-Sulfonyl Chloride
CAS Number 74863-82-4
CAT Number RF-PI269
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H8ClNO2S
Molecular Weight 241.69
Density 1.4±0.1 g/cm3
Refractive Index 1.63
Solubility Soluble in Chloroform
Shipping Condition Shipped Under Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White Crystalline Powder
Purity / Analysis Method >98.0% (HPLC)
Melting Point 162.0~163.0℃
Loss on Drying <0.50%
3-Methylquinoline-8-Sulfonic Acid <1.00%
Total Impurities <2.00%
Infrared Spectrum Conforms to Structure
NMR  Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Argatroban (CAS 74863-84-6)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moisture

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 3-Methyl-8-Quinolinesulphonyl Chloride (CAS: 74863-82-4) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and Active Pharmaceutical Ingredient (API) synthesis. It is an intermediate typically in the synthesis of Argatroban (CAS: 74863-84-6) or Argatroban Monohydrate (CAS 141396-28-3).

Argatroban (CAS: 74863-84-6) is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.  

  • Write your message here and send it to us